A once-a-day, low-impact oral GLP-1 pill known as CX11 has passed its efficacy test on US patients to advance to the first North American Phase 3 trial. It's already cleared its first Phase 3 study in China.
Start Your NewsReadery Pro FREE TRIAL!
| | |
newatlas.com / .newatlas-com-medical / Page 3
Medical
A landmark study due to start in the coming months aims to test a method for rejuvenating our immune system in older age. The Phase 1 trial will target senescent T cells, which accumulate as we age or fight chronic disease and become less good at ...
University of California, San Francisco (UCSF) scientists have developed a form of neurological pacemaker that adapts in real time to a patient's walking and could address one of the most disabling and hard-to-treat symptoms of Parkinson's disease.
Definium Therapeutics has announced strong results in a phase 3 trial of its single-dosed lysergide (LSD) drug DT120 in treating adults with major depressive disorder (MDD), meeting its primary goal and all key secondary efficacy endpoints in the ...
People taking fish-oil supplements in an effort to shield their brain from Alzheimer's disease (AD) might be better off investing that money in their diet, with a two-year study finding that omega-3 pills offer no protection from cognitive decline.
Scientists have not just uncovered a new way that aging cells drive inflammation, but they've also blocked this pathway with an existing Food and Drug Administration-approved medicine. This opens the door to an entirely new way to shield the body ...
Nadine Wehida & Ahmed Elbediwy, Kingston University/The Conversation ...
Sold under brand names like Wegovy and Ozempic, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a popular way to curb appetite and lose weight.
David Michaels, George Washington University & Robert Harrison, University of California, San Francisco/The Conversation ...
We may be on the cusp of understanding whether we can turn back time for our cells to stave off age-related disease, with the first human receiving experimental gene therapy as part of a landmark trial.